|Bid||2.3900 x 3000|
|Ask||2.4000 x 2900|
|Day's Range||2.2600 - 2.4900|
|52 Week Range||1.0500 - 2.7500|
|Beta (3Y Monthly)||3.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.17|
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...
Novavax, Inc. (NVAX) today announced the promotion of Jill Hoyt to Senior Vice President of Human Resources and Biegie Lee to Vice President of Information Technology. Jill and Biegie are vital parts of a seasoned executive team striving to accomplish our near and long-term corporate objectives," said Stanley Erck, President and Chief Executive Officer of Novavax, Inc. “Jill has been working with me and the senior leadership team to hire, develop and support employees of this company, which is consistently being recognized as one of the best in the biopharmaceutical industry. Ms. Hoyt joined Novavax in 2008 with full responsibility for its human resources duties and activities.
HENDERSON, NV / ACCESSWIRE / December 4, 2018 / The following stocks in the CBD/Biotech sectors look poised for big December's. Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), CV Sciences, ...
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Wall Street closed up on Monday as oil prices stabilized and giant tech stocks such as the FAANG (Facebook, Amazon, Apple, Netflix and Google-parent Alphabet), ...
CORAL GABLES, FL / ACCESSWIRE / November 26, 2018 / Healthcare stocks remain popular during the latest bout of selling pressure within the broader markets. The Frost & Sullivan Healthcare and Life Sciences experts are predicting big disruptions, transformationsand innovations in the coming years as the healthcare industry continues to overhaul outmoded business models. "Our interactive workshop is designed to help managers and CEOs understand key issues affecting the healthcare industry globally," noted Sandeep Sinha, Vice President & Head, Healthcare and Life Sciences, Frost & Sullivan.
Novavax, Inc. (NVAX) today announced several management promotions. “We are pleased to announce several key management promotions to further support the advancement of our company and its lead clinical programs into commercial stage," said Stanley Erck, President and Chief Executive Officer of Novavax, Inc. “These individuals have worked closely with our senior leadership team and have made significant contributions to ensure we drive our ResVax and NanoFlu programs towards licensure.
Stan Erck has been the CEO of Novavax Inc (NASDAQ:NVAX) since 2011. First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at a Read More...
Novavax is a few months away from results for its two lead vaccine programs — and it's taking steps “to enable us to launch our products as soon as possible post licensure,” CEO Stanley Erck said on a Wednesday earnings call.
Novavax (NVAX) delivered earnings and revenue surprises of 0.00% and -23.91%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Gaithersburg, Maryland-based company said it had a loss of 12 cents per share. The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md., Nov. 07, 2018 -- Novavax, Inc., (Nasdaq: NVAX) today announced its financial results and operational.
On Wednesday, Nov. 7, Novavax, Inc. (NASDAQ: NVAX ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue Wall ...
GAITHERSBURG, Md., Nov. 01, 2018 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter 2018 financial and operating results following the close of.
GAITHERSBURG, Md., Nov. 01, 2018 -- Novavax, Inc., (Nasdaq: NVAX) today announced the appointment of Rachel King, Co-Founder and Chief Executive Officer of GlycoMimetics, Inc.,.
Investors are looking forward to Novavax's (NVAX) updates on its pipeline candidates when it reports third-quarter 2018 results.
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Novavax, Inc. (NVAX), a biotechnology company focused on the discovery and development of innovative vaccines to prevent serious respiratory diseases. The company's products are targeted for worldwide markets and its core commercial team is already laying the groundwork before launching with government policymakers, provider, payers, associations, advocates and opinion leaders in advance of regulatory approval.